Letizia Amadori, Claudia Calcagno, Dawn M Fernandez, Simon Koplev, Nicolas Fernandez, Ravneet Kaur, Pauline Mury, Nayaab S Khan, Swathy Sajja, Roza Shamailova, Yannick Cyr, Minji Jeon, Christopher A Hill, Peik Sean Chong, Sonum Naidu, Ken Sakurai, Adam Ali Ghotbi, Raphael Soler, Natalia Eberhardt, Adeeb Rahman, Peter Faries, Kathryn J Moore, Zahi A Fayad, Avi Ma'ayan, Chiara Giannarelli
The development of new immunotherapies to treat the inflammatory mechanisms that sustain atherosclerotic cardiovascular disease (ASCVD) is urgently needed. Herein, we present a path to drug repurposing to identify immunotherapies for ASCVD. The integration of time-of-flight mass cytometry and RNA sequencing identified unique inflammatory signatures in peripheral blood mononuclear cells stimulated with ASCVD plasma. By comparing these inflammatory signatures to large-scale gene expression data from the LINCS L1000 dataset, we identified drugs that could reverse this inflammatory response...
June 2023: Nat Cardiovasc Res